Slow-cycling and treatment-resistant cancer cells escape therapy, providing a rationale for regrowth and recurrence in patients. Much interest has focused on identifying the properties of slow-cycling tumor cells in glioblastoma (GBM), the most common and lethal primary brain tumor. Despite aggressive ionizing radiation (IR) and treatment with the alkylating agent temozolomide (TMZ), GBM patients invariably relapse and ultimately succumb to the disease. In patient biopsies, we demonstrated that GBM cells expressing the proliferation markers Ki67 and MCM2 displayed a larger cell volume compared to rare slow-cycling tumor cells. In optimized density gradients, we isolated a minor fraction of slow-cycling GBM cells in patient biopsies and tumorsphere cultures. Transcriptional profiling, self-renewal, and tumorigenicity assays reflected the slow-cycling state of high-density GBM cells (HDGCs) compared to the tumor bulk of low-density GBM cells (LDGCs). Slow-cycling HDGCs enriched for stem cell antigens proliferated a few days after isolation to generate LDGCs. Both in vitro and in vivo, we demonstrated that HDGCs show increased treatment-resistance to IR and TMZ treatment compared to LDGCs. In conclusion, density gradients represent a non-marker based approach to isolate slowcycling and treatment-resistant GBM cells across GBM subgroups.
Introduction
A cardinal feature of malignancy is the aberrant proliferation of cancer cells. Early observations showed that radiotherapy and treatment with chemotherapeutics effectively target fast-cycling tumor cells, resulting in reduced tumor growth and increased overall survival in cancer patients. Dormant or slow-cycling cancer cells, sometimes termed "persister cells" [1, 2] , evade anti-proliferative therapies and reestablish heterogeneous cancers [3] . Emerging evidence suggested that genetic alterations are insufficient to account for the versatile behavior of slow-cycling cancer cells and that cancer dormancy is driven designed to target actively proliferating tumor cells. Slow-cycling primary GBM cells displayed TMZ resistance [5, [11] [12] [13] and promoted tumor invasion [11, 13] . DNA bar-coding showed that slow-cycling and treatment-resistant GBM cells enriched for stem cell genes gave rise to fast-cycling and more differentiated GBM cells [5] . Proliferating GBM cells in tumorsphere cultures maintained label-retaining tumor cells in a reversible slow-cycling and chemoresistant state [12] , and reversibly transitioned into a slow-cycling persistent state in response to targeted kinase inhibitors [6] . A better understanding of these dynamic lineage relationships between slow-cycling, proliferating, and more differentiated GBM cells is important to develop therapies that prevent recurrence in patients.
Recent advances have revealed the molecular mechanisms that activates quiescent neural stem cells (NSCs) in the ventricular-subventricular zone (V-SVZ) lining the lateral ventricles [14] . V-SVZ stem cells have been proposed as the cell of origin for GBM in mice and humans [15] . Ionizing radiation (IR) depleted activated stem cells, fastcycling progenitors, and proliferating neuroblasts while leaving behind quiescent NSCs that later reestablished the neurogenic V-SVZ lineage in adult mice [16] [17] [18] . In a NSC-derived GBM model, TMZ treatment left behind a subpopulation of slow-cycling tumor cells displaying NSC properties and repropagated tumors [19] . Prospective isolation based on Prominin 1 (the mouse homolog of CD133) showed distinct transcriptional signatures of quiescent and activated NSCs [20] . Quiescent NSCs produced few primary neurospheres compared to activated NSCs [20] . Similar to activated NSC, CD133+ GBM stem cells showed robust proliferative activity and generation of primary tumorspheres, reflected in their superior tumorigenicity in xenotransplantation assays [21] [22] [23] [24] . Thus, CD133 expression is not sufficient to differentiate between slowcycling and fast-cycling GBM stem cells. Additionally, CD133 and other surface antigens are not universally expressed in GBM stem cells across GBM subgroups [21, [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Somatic stem cells increased in cell size as they transition from a quiescent to an alert state [33] . In fact, all mammalian cells increase in cell size and buoyant mass as they prepare to enter the mitotic phase of the cell cycle [34, 35] . It remains unknown whether cell size and cell density represents defining features of slow-cycling and treatment-resistant human GBM cells. Density gradients have been used to enrich for NSCs and glial progenitors. In contrast to more differentiated neural cell types, NSCs display increased cell density [36, 37] . NSCs can also be enriched in mixed cell populations as neurospheres by culturing disaggregated CNS tissue in serum-free media supplemented with growth factors [36, 38] . Pioneering studies employing density gradients in human glioma were able to separate tumor and stromal cell populations that improved the success rate of establishing primary glioma cultures [39] [40] [41] [42] . Recently, density gradients were employed to separate highly tumorigenic hepatic cancer stem cells from the remaining tumor bulk in a hepatocellular carcinoma model [43] . To our knowledge, no other studies have used density gradients to isolate slow-cycling and treatment-resistant GBM cells.
Histological examinations of GBM biopsies identified a rare population of small (3-5 µm) tumor cells that lack expression of proliferation markers. Using a colloidal silica-based media, we optimized continous and discontinuous density gradients to fractionate cells in tumor biopsies and tumorsphere cultures from GBM patients. A minor fraction of high-density GBM cells (HDGCs) was characterized by a small cell volume and generated fast-cycling low-density GBM cells (LDGCs). The slow-cycling state of HDGCs was reflected in tumorsphere formation assays, transcriptional profiling, and tumorigenicity in patient-derived xenografts (PDXs). HDGCs showed a striking resistance to IR and TMZ treatment.
In conclusion, density gradients represent a non-marker based approach to isolate slow-cycling and treatment-resistant GBM cells, an important target for future therapies.
Materials and methods

Cell culture
Tumor biopsies were provided by UCSF's Brain Tumor Research Center Tissue Bank and acquired from primary GBM patients undergoing surgery at the UCSF Department of Neurological Surgery. Tissues (SF9256, SF9269, SF9272, SF9274, SF9437, and SF9532) were collected from patients given their consent and de-identified according to protocols approved by the UCSF Committee on Human Research. The GBMs were passaged as intracranial xenografts in athymic nu/nu mice (Charles River) and established as tumorsphere cultures using defined media. The biopsies were dissociated using papain and cell cultures were established using neurobasal (NBE) media (-A, Invitrogen) supplemented with 1% v/v B27 supplement (Gibco), 0.5% v/v N2 supplement (Gibco), 20 ng/ml FGF-2 (Peprotech), 20 ng/ml EGF (SigmaAldrich), 2 mM L-glutamine, Pencillin/streptomycin and incubated at 37°C in 5% CO 2 . In addition, we used a set of primary human GBMs (GBM5, GBM12, GBM14, GBM34, GBM43) as xenografts and dissociated tumorspheres that were acquired from David James at the Mayo Clinic, MN [44] . Tumorspheres were passaged using enzymatic dissociation with Accutase (Innovative Cell Technologies).
Density gradients protocols
To generate continous density gradients, BactXtractor High Density (Bx-H, Fertipro N.V.) with a starting density of 1.3 g/ml was diluted with phosphate-buffered saline (PBS) to generate a Stock Isotonic BactXtractor (SIB) solution with density 1.13 g/ml. We mixed different ratios of SIB solution and PBS (10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:10) to optimize density gradients for efficient separation of tumor cells. For the tumor sample, we diluted 5 ml of SIB solution with 5 ml PBS (final density of 1.065 g/ml after adding cells dissociated in 0.4 ml PBS) in a 15-ml plastic tube (Fisherbrand). In a separate tube, we diluted 5 ml of SIB solution with 4.9 ml PBS and 100 μl of density marker beads (Sigma-Aldrich). After manually inverting centrifuge tubes approximately ten times, the samples were centrifuged 15,000×g for 30 min at 18°C using an angled rotor (5810R, Eppendorf). No brakes were used during centrifugation. The tubes were allowed to stand for 30 min while we dissociated and counted GBM cells using a hemocytometer. Following centrifugation (700 rpm for 5 min) of cells, we resuspended cells in 0.1 ml of 3:1 Bx-H:PBS. Using the flotation technique, cells were slowly loaded with a glass pipette at the bottom of a tube containing a diluted density solution (1.065 g/ml). Separate tubes loaded with either GBM cells or density marker beads were centrifuged at 1500×g for 15 min at 18°C using a spinn-out rotor (5810R, Eppendorf). The spinn-out rotor was used for all subsequent centrifugations. After initially isolating four different fractions based on the position of marker beads, we decided to use 1.06 g/ml and 1.08 g/ml to separate cells into LDGC, MDGC, and HDGC fractions. To avoid losing cells at different densities, we added 5 ml of PBS to the sample tube and centrifuged cells at 800 rpm for 7 min. After the centrifugation, we removed the upper fluid to the 9 ml mark of the 15-ml tube, added 6 ml PBS, inverted the tubes multiple times to dilute the gradients, and followed with another centrifugation. We then removed fluid to the 6 ml mark of the tube, added 9 ml PBS, inverted the tube multiple times, followed by another centrifugation step. To successfully extract cells at the HDGC fraction, we repeated the washing procedure one additional time. To separate GBM cells using discontinuous gradients, we diluted BX-H with different ratios of PBS to generate five 2 ml layers with densities: 1.00 g/ml, 1.065 g/ml, 1.12 g/ml, 1.15 g/ml and 1.225 g/ml. The layers were carefully added to a 15-ml centrifuge tube and then centrifuged 15,000×g for 30 min at 18°C using an angled rotor. Tumor biopsies dissociated with papain or tumorspheres dissociated with accutase were counted and carefully loaded at the bottom of 15-ml tubes (Fisherbrand) using a glass pipette. In parallel, we loaded a tube with 100 μl density marker beads. Similar to continous gradients, we centrifuged tubes at 1500×g for 15 min at 18°C using a spinn-out rotor (5810R, Eppendorf). We then carefully collected cells at the interfaces between density fractions and performed three washes with PBS.
Immunocytochemistry
Human GBM tumorspheres before or after separation with density gradients into LDGC, MDGC, and HDGC fractions were plated on polyornithine/laminin coated 24-well plates at a density of 1 (1:1000, Invitrogen) for 45 min at room temperature. We incubated fixed cells with phalloidin-568 (1:100, Life Technologies) in PBS+ for 2 h at room temperature. After 3 × PBS (DAPI was included in one wash), the cells were mounted using Aquamount (Polysciences), and images were captured using a Zeiss 780 confocal microscope or an Eclipse E800 fluorescence microscope.
Immunohistochemistry
Patient biopsies from three human GBMs (SF10281, SF10282, and SF10286) were fixed for 24 h in 10%-formalin buffered solution, paraffin-embedded, sectioned (5 µm), and dehydrated. Sections were processed for hematoxylin & eosin (H&E) stainings (Ventana, UCSF BTRC Tissue Core). A well-characterized antibody recognizing p53 was used as an indirect measure of TP53 status [45] . Patient biopsies were also acutely fixed in 4%-paraformaldehyde for 24 h, washed in PBS, and then transferred to 30% sucrose for 24 h. After three PBS washes, we incubated 20 µm frozen sections in PBS+ for 30 min. Sections were incubated with phalloidin-568 (1:100, Life Technologies) or antibodies against Ki67 (1:500, eBiosciences or BD Pharmingen), MCM2 (1:200, Santa Cruz Biotechnology), SOX9 (1:500, R&D Systems), GFAP (1:1000, Abcam), and OLIG2 (1:500, EMD Millipore) in PBS+ at room temperature overnight followed by three PBS washes. Sections were incubated with species-specific Alexa488, 555 or 647-conjugated secondary antibodies for 45 min at room temperature. After 3 × PBS (DAPI was included in one wash) the sections were mounted using Aquamount (Polysciences). We captured images with a Zeiss 780 confocal microscope or an Eclipse E800 fluorescence microscope.
Cell volume measurements
To measure cell and nucleus volume in 4%-PFA fixed biopsies from three human GBM patients (SF10281, SF10282, and SF10286), we used sections stained with antibodies against Ki67, MCM2 and DAPI as stated above, and performed z-stacks using a Zeiss 780 confocal microscope. We also measured nucleus volume of SOX9 and OLIG2 expressing tumor cells in sections from human GBM patients. For measurement of cell and nucleus volume following density gradients of GBM tumorsphere cultures, we stained cells with phalloidin and DAPI as stated above and performed z-stacks using a Zeiss 780 confocal microscope. Cell and nucleus volumes were measured using Imaris 8.0.1 software (Bitplane Inc.). We excluded data points for cell aggregates. We calculated mean nuclear volumes of > 120 cells in five confocal z-stacks (×63 magnification) for each biopsy.
Self-renewal assay
To assess sphere-forming ability, tumor cells from LDGC and HDGC density fractions were plated in NBE media at 5 cells/well in ultralowadherent 96-well plates (Corning). Ten days later, we quantified the number of primary tumorspheres. We then dissociated the spheres and replated the cells for secondary sphere-formation. Experiments were performed in triplicates from three separate passages.
Proliferation assay
To assess proliferation for different density fractions from human GBM tumorspheres, we plated 0.2 × 10 4 GBM43 cells per well in NBE media on polyornithine/laminin coated 96-well plates and analyzed the DNA content between 0 and 8 days using the Cyquant NF proliferation assay (Life Technologies) [28] . In brief, cells were lysed and simultaneously incubated at 37°C with a fluorescent probe to label non-fragmented DNA as an indirect measure of the number of cells. The fluorescence intensity was measured at Ex/Em + 485 nm/530 nm using a Tecan microplate reader. A standard curve was generated by plotting # of plated cells (1000-40,000) against corresponding fluorescent values, resulting in the equation y = x + 150, R 2 = 1. The # cells in each sample were calculated using this equation. Experiments were done in triplicates.
Quantitative real-time polymerase-chain reaction (qRT-PCR)
Following density gradient separation, pelleted GBM cells were homogenized using the QIAshredder spin column (Qiagen). Total RNA was extracted from specimens using RNeasy mini kit (Qiagen) and contaminating RNA was digested using RNase free DNase kit (Qiagen). cDNA was synthesized using 500 ng total RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) or SuperScript VILO (Life Technologies). Real time PCR was performed with the intron-spanning primers (5 μM) listed below and KAPA SYBR fast ABI prism qPCR master mix (KAPA biosystems) on a 7900 HT Fast RealTime PCR system (Applied Biosystems). The following forward and reverse primers were used: hHES1; GTCAACACGACACCGGATAAACCA and TTTCCAGAATGTCCGCCTTCTCCA, hSOX9; TCTGAACGAGAGCGA GAA and GCGGCTGGTACTTGTAATC, hSOX2; GCACATGAACGGCTGG AGCAACG and TGCTGCGAGTAGGACATGCTGTAGG, hCMYC; ACAGC ATACATCCTGTCCGTCCAA and TGTTCTCGTCGTTTCCGCAACAAG, hNANOG; TCCCAAAGGCAAACAACCCACTTC and AGCTGGGTGGAAG AGAACACAGTT, hOCT4; TATGCAAAGCAGAAACCCTCGTGC and TTC GGGCACTGCAGGAACAAATTC, hHEME3; TGCACGGCAGCTTAACGAT and AGGCAAGGCAGTCATCAAGG. Relative changes in gene expression from quantitative PCR data were calculate from threshold cycle with the 2 -ΔΔ-Ct method as reported [46] . Transcript levels were normalized against corresponding HEME3 levels expressed as mean fold changes ± standard deviation.
Fluorescence-activated cell sorting (FACS)
For GBM tumorsphere cultures, we stained GBM cells with combinations of the following conjugated antibodies proposed to label GBM stem cells: CD44-PE (1:20, R&D systems), PDPN-PE (1:50, Angiobio), CD133-APC (1:40, clone 293C, Miltenyi Biotech), and CD15-FITC (1:40, DAKO). As controls, primary antibodies were replaced by isotype-matched antibodies from the same manufacturers. To study cell cycling in different density fractions, cells were dissociated with Accutase, fixed in 70% ethanol at + 4°C overnight, nuclei were stained with 5 μg/ml propidium iodide containing 125 units/ml RNase for 30 min and were analyzed with a FACS Calibur flow cytometer (Becton Dickinson). DNA histograms were modeled offline using Modfit-LT software (Verity Software). Apoptosis was detected by measurement of sub-G 1 fraction. To study proliferation for different density cell fractions, we added the cell-permeable CellTrace Carboxyfluorescein succinimidyl ester (CFSE) proliferation dye diluted in DMSO (5 μM, Life Technologies) to dissociated GBM tumorspheres in NBE media for 20 min at 37°C, performed a wash with five volumes NBE media containing 1% bovine serum albumin, resuspended cells in fresh NBE media following centrifugation, and performed density gradients of GBMs after 0, 4, and 8 days culturing. The CFSE levels were analyzed by flow cytometry. Calculations and preparation of images were performed using FlowJo version 7.6.5 software (Treestar Inc.).
Microarray analysis
Human GBM tumorspheres (GBM5, GBM12, GBM14, GBM34, and GBM43) were cultured in NBE media and separated using continuous density gradients (d: 1.065 g/ml). We washed and pelleted GBM cells from LDGC and HDGC fractions and total RNA was prepared as mentioned in qRT-PCR section (Qiagen). The concentration and quality of RNA was determined using Nanodrop followed by use of a RNA 6000 Nano Kit (Agilent) and bioanalyzer chips (Applied Biosystems) to determine RIN values. We then sent 300 ng total RNA (50 ng/ml) to the UCSF Institute for Human Genetics for further processing. In brief, 150 ng was used in the first and second strand cDNA synthesis and IVT cRNA synthesis. We then performed cRNA purification and samples were normalized to 13.33 μg cRNA in 24 μl volume. Samples then went through a second cycle of cDNA synthesis and RNase H hydrolysis. The cDNA was purified and normalized to 5.5 μg cDNA in 31.2 μl volume. We then performed cDNA fragmentation, labeling, and hybridized 90 μl of the sample in the Affymetrix GeneTitan Hybridization Oven instrument for 16 h at 48°C. The arrays were processed with the Affymetrix GeneTitan Fluidics Station instrument, using the HuGene-1_1-st-16 fluidics script and GeneTitan Hybridization, Wash, and Stain Kit for WT Array Plates. Next, the arrays were scanned in the Affymetrix GeneTitan Multi-Channel (MC) instrument with the AGCC GeneTitan Instrument Control. Quality control of samples was performed using the Affymetrix Expression console and data was initially analyzed using Affymetrix Transcriptome Analysis Console. CEL files were normalized by RMA using the oligo package in R [47] . Differential expression was assessed by paired T test using the samr package with a 10% False Discovery Rate threshold [48] , and Gene Ontology enrichment analysis was assessed using BiNGO [49] . Raw microarray data for this study has been deposited at the Gene Expression Omnibus (GEO) repository under accession GSE71116.
Xenograft studies
To study tumor growth of human GBM43 cells separated using density gradients and the effect of IR on the survival of human GBM fractions in vivo, we perform intracranial injections of 300,000 GBM43 cells expressing the firefly luciferase (LUC) gene and enhanced green fluorescent protein (EGFP) into the frontal cortex of 4-6 week old athymic nu/nu mice. Injections were done at a depth of 3 mm and the coordinates were 1.5 mm anterior and 1.0 mm lateral of the right hemisphere relative to Bregma. We measured body weight and bioluminescence every 2nd day during tumor progression. Three days following IR, we euthanized the IR and non-IR mice using CO 2 and cervical dislocation, dissected intracranial GBMs, dissociated tumor cells using Accutase, followed by immediate flow cytometry or loading of cells onto prepared continous density gradients (d: 1.065 g/ml). Bioluminescence was measured using a Xenogen IVIS imager and survival was plotted using Kaplan-Meier curves. Symptomatic mice were sacrificed according to ethical guidelines approved by the UCSF Institutional Animal Care and Use Committee (IACUC).
Ionizing radiation
Mice and cells were placed in a cesium-137 source (J.L. Shepherd & Associates) irradiator. Mice were shielded with iron collimators to focus the beam to the brain. As the bioluminescence levels reached 10 7 photons/s, mice were given a 5 Gy dose cranial irradiation. Similarly, tumorsphere cultures were exposed to a single dose of 10 Gy.
Statistical analysis
Statistical tests were performed using GraphPad Prism v6.0 software. Statistical analyses for experiments with two groups were performed using Student's t-test. Statistical analyses for experiments with more than two groups were performed using two-way ANOVA with Fisher's posthoc test or one-way ANOVA with Dunnett's multiple comparison posthoc test (for in vitro proliferation and therapy studies). Kaplan Meier survival analysis was conducted and the p value of the comparison between survival curves was determined to be significant by the log-rank (Mantel-Cox) test.
Results
Histological identification of small and slow-cycling tumor cells in human GBM
Analyses of three different human GBM tumor biopsies revealed intermixed populations of large and small cells displaying nuclear atypia (Fig. 1A-C) . Consistent with tumor cells, both large and small cells were p53 immunopositive, indicative of TP53 mutation (Fig. 1D ). After confirming a correlation between total cell and nuclear volume (data not shown), we measured the nuclear volume in Ki67-MCM2-, Ki67-MCM2+, and Ki67+MCM2+ cells using z-stacks from 20 µm thick paraformaldehyde-fixed biopsies (Fig. 1E-F) . Quantification showed that fast-cycling tumor cells expressing proliferation markers displayed an increased (p < 0.001) nuclear volume compared to slowcycling and marker-negative GBM cells (Fig. 1G-H, Fig. S1A-B) .
Small GBM cells display high density in patient biopsies and tumorsphere cultures
To isolate slow-cycling tumor cells in patient-derived GBM biopsies and tumorsphere cultures, we employed a silica-based media to establish continuous density gradient protocols for separation of LDGC, medium-density GBM cell (MDGC), and HDGC fractions displaying low (d < 1.06 g/ml), medium (1.08 g/ml > d > 1.06 g/ml), and high (d > 1.08 g/ml) density, respectively ( Fig. 2A, Fig. S2A-C) . To minimize contamination of cells throughout the gradient, we employed a flotation technique that allowed cells to migrate against the centrifugal force [50] . The observed densities of GBM cell fractions in continuous gradients enabled us to optimize discontinuous gradients where cell fractions were condensed at the interface between layers of pre-determined densities. We identified 72 ± 5% LDGCs, 23 ± 4% MDGCs, and 5 ± 2% HDGCs in tumor biopsies from GBM patients (mean ± SEM, n = 5) (Fig. 2B) . Using density gradients on two well-characterized human GBM xenograft cultures (GBM14 and GBM43) [28, 51] , we found a similar distribution of cells after density separation of human tumor biopsies and human GBM tumorspheres. We found 1-2% HDGCs in GBM43 and GBM14 tumorsphere cultures (Fig. 2C) . To analyse the cell volume of cells in density fractions, GBM43 cells were cultured on coated plates directly following density gradient separation and stained for Phalloidin (F-actin; cytoplasm) and DAPI (nuclei) (Fig. 2D) . Volume measurements showed that GBM43 HDGCs display a smaller (P < 0.001) cell volume compared to LDGCs (Fig. 2E-F, Fig. S2D ). To further confirm the difference in cell volume between density fractions, we used flow cytometry to measure granularity and cell size through side-scatter and forward scatter, respectively. We found that HDGCs displayed increased side-scatter and reduced forward scatter levels ( Fig.  S2E-F) , providing a rationale for their increased cell density compared to LDGC fractions.
High density is a property of slow-cycling GBM cells
Multiple reports show an association between cell size and a slowcycling state in stem cells and cancer stem cells [28, 33] . Similar to patient-derived biopsies (Fig. 1E-H) , proliferating Ki67+ cells in GBM tumorsphere cultures displayed an increased cell size compared to Ki67-cells (Fig. 3A) . To study proliferative activity of tumor cells in density fractions, GBM43 tumorsphere cultures were separated using density gradients and cellular DNA was stained with propidium iodide. We found that~75% of HDGCs were found in the resting state (G1) compared to 57% for LDGCs (Fig. 3B) . Quantification of unfragmented DNA (CyQuant assay) as an indirect measurement of cell proliferation in GBM43 tumorsphere cultures showed significantly increased proliferation of LDGCs compared to HDGCs (P < 0.001, n = 3, Fig. 3C ). Slow-cycling HDGCs displayed reduced primary (proliferation) and secondary (self-renewal) tumorsphere formation compared to LDGCs (P < 0.001, Fig. 3D ). To confirm the slow-cycling state of HDGCs at a single cell level, GBM43 cells were first stained with carboxyfluorescein succinimidyl ester (CFSE, 50% dilution per cell division), separated using density gradients, and then measured for CFSE levels using flow cytometry (Fig. 3E) . Approximately 50% of the HDGCs maintained high CFSE levels 8 days later, confirming their slow-cycling state (Fig. 3F ). In contrast, the level of CFSE was completely depleted in the LDGC fraction after 8 days confirming their highly proliferative state (Fig. 3F) . To determine whether there is a lineage relationship between HDGCs and LDGCs, we performed density gradients of GBM43 cells and then expanded fractions followed by a 2nd round of density gradients (Fig. 3G) . A fraction of HDGCs entered mitosis a few days after isolation and generated LDGCs two weeks later (Fig. 3H-I ). It remains unclear whether the few HDGCs found in the LDGC fraction represents a reversible process or contamination of aggregating cells. Thus, we conclude that slow-cycling HDGCs can repopulate GBM tumorsphere cultures.
Transcriptional profiling reflects the slow-cycling state in high-density GBM cells
Analysis of GBM biopsies showed that both OLIG2 and SOX9 were expressed in GBM cells displaying a wide range of cell volumes. Quantification of nuclear volumes showed that SOX9 was expressed in particularly small GBM cells (Fig. 4A-B, Fig. S3 ). We confirmed that SOX9 was expressed in both small and large tumor cells in SF9256 GBM , and Ki67-MCM2-cells that were (H) quantified for three patient-derived GBM specimens. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
tumorsphere cultures (Fig. 4C) . To study expression of transcription factors expressed in GBM stem cells, we performed quantitative realtime PCR (qRT-PCR) on density fractions from five GBM tumorsphere cultures (Fig. 4D, Fig. S4A ). The SRY-Box family members SOX2 and SOX9, the Notch target gene HES1, and the reprogramming factor c-MYC showed variable expression levels across density fractions (Fig. 4D) . More strikingly, HDGCs expressed 10-100 fold increased levels of the reprogramming genes NANOG and OCT4 compared to LDGC fractions (Fig. 4D) . Immunocytochemistry studies showed that small tumor cells expressed SOX2, SOX9, Nestin, and GFAP in GBM43 tumorsphere cultures (outlined cells in Fig. 4E ). These GBM tumorsphere cultures showed variable overlap of the GBM stem cell antigens PDPN and CD133 (Fig. S4B-C) . HDGCs, MDGCs. and LDGCs showed variable expression of proposed GBM stem cell antigens (CD15, PDGFRB, CD44, α6-integrin, CD133, and PDPN) in GBM43 tumorsphere cultures (Fig.  S4D) . In GBM tumorspheres displaying transcriptomes ranging from proneural (GBM5), classical (GBM12, GBM14) to mesenchymal (GBM43, GBM34) signatures (Fig S5) , we isolated total RNA and used Affymetrix microarrays to identify gene expression profiles in HDGC and LDGC fractions (Fig. S5A-B) . Hierarchical clustering showed that individual samples derived from the same patient clustered most closely to each other (Fig. S5C) . Differential gene expression analysis comparing levels in HDGC and LDGC samples identified only 25 genes showing > 2-fold up-regulation of gene expression at a ≤ 10% False Discovery Rate. A larger number of genes were differently expressed in HDGCs compared to LDGCs when tumors were divided into proneural (GBM5/GBM12/GBM14) and mesenchymal (GBM34/GBM43) human GBMs (data not shown). Using a lower threshold of 30% fold-change between density fractions, we identified differentially expressed genes in LDGC versus HDGC fractions (Fig. S5D) . Gene ontology analysis demonstrated up-regulation of many genes involved in mitosis (Fig. 4F , P < 7 × 10 -7 ) and down-regulation of a smaller set of genes (Fig. 4G) in LDGCs compared to HDGCs. For example, cyclin-dependent kinase 1 (CDK1) and dopamine receptor 5 (DRD5) were up-and down-regulated in LDGCs, respectively (Fig. 4H ).
In conclusion, we demonstrate that HDGCs and LDGCs display common expression of transcription factors, variable labeling by cell surface antigens, and few differentially expressed genes in GBM tumorsphere cultures.
High-density GBM cells display reduced tumorigenicity and increased treatment-resistance
The superior ability to generate tumors following intracranial xenotransplantation is a hallmark of GBM stem cells [24] . To test the ability of different density fractions to generate tumors after xenotransplantation, we transduced GBM43 cells with enhanced green fluorescent protein (EGFP) and the firefly luciferase (LUC) gene to enable bioluminescence imaging in vivo. Following density gradient separation, we performed orthotopic injections of transduced GBM43 cells into immunocompromised mice. We performed bioluminescence imaging every 2nd day and found that LDGCs produced fast-growing tumors with significantly increased tumor growth compared to HDGCs (n = 5, P < 0.001) (Fig. 5A-B) . As a result of decreased tumorigenicity, mice with HDGC xenografts survived significantly longer than mice with LDGC xenografts (P < 0.001) (Fig. 5C ). To compare treatment-resistance of different density fractions, tumorsphere cultures (GBM14 and GBM43) were exposed to IR (10 Gy) or incubated with TMZ (100 μg/ml) for seven days followed by density gradient separation (Fig. 6A) . The number of LDGCs in GBM14/GBM43 tumorspheres was significantly reduced following IR or TMZ treatment compared to untreated control tumorsphere cultures (Fig. 6B-C, n = 3 ). In contrast, we found no significant changes in the number of HDGCs in treated versus untreated control cultures, demonstrating treatment-resistance for this high-density cell fraction in vitro. To study radioresistance in vivo, we performed orthotopic injections of GBM43-LUC/EGFP cells into mice that were subsequently randomised into a control group and a treatment group that was exposed IR (5 Gy, n = 3). Randomization was based on bioluminescence imaging as a measure tumor size. To evaluate the acute effect of IR on tumor growth, mice were imaged right before IR exposure (Day 0) and 3 days later (Day 3). In accordance with our previous data [28] , we found that a single dose IR effectively slows down tumor growth in GBM43 xenografts (Fig. 6D-E ). Mice were euthanized 3 days after exposure to IR, tumors were dissociated and separated using density gradients, and flow cytometry was used to quantify the number of EGFP+ cells in each density fraction (Fig. 6F) . Quantification showed significantly increased numbers of EGFP+ HDGCs and reduced numbers of EGFP+ LDGCs (Fig. 6F) following IR of GBM xenografts. Thus, we demonstrated that HDGCs produced in vivo tumors with increased latency, yet displayed increased treatment-resistance, compared to xenografted LDGCs. 
Discussion
The failure of anti-proliferative therapies to target slow-cycling cancer cells remains a major obstacle to prevent regrowth in cancer patients. GBM cells exist in slow-and fast-cycling states [5, 12, 13] . Given that variation in cell size has been linked to cell proliferation [35, 52] , we established density gradient protocols to separate slowcycling tumor cells from fast-proliferating and more differentiated GBM cells. The slow-cycling state of a rare population of small HDGCs was reflected in reduced proliferation, poor primary tumorsphere formation, and extended latency in xenotransplantation assays. HDGC and LDGC fractions shared expression of stem cell-associated transcription factors, cell surface antigens, and transcriptional signatures in GBM tumorsphere cultures, suggesting that epigenetic or post-transcriptional mechanisms are responsible for the slow-cycling and treatment-resistant state of HDGCs.
In contrast to flow cytometry, density gradients represent a markerindependent approach to separate slow-and fast-cycling GBM cells. We anticipate that use of density gradients to separate human GBM cells can readily be adapted for other types of solid cancers. Our data suggest that the MDGC fraction contains cells in a transitional state and a mixture of cells from HDGC and LDGC fractions, allowing for further optimization and use of discontinuous gradients. Therefore, our experiments focused on the HDGC and LDGC fractions throughout the study. Further optimization of discontinuous density gradients should generate more efficient separation of stroma components and tumor cells from patient specimens. A combination of density gradients followed by flow cytometry should further separate cell populations within heterogeneous tumors.
Expansion of primary GBMs in defined media supplemented with growth factors as tumorspheres [53] or as adherent cells [54] maintains tumor cells in an undifferentiated and stem cell-like state. In contrast, serum-containing media differentiates tumor cells, produces novel genetic aberrations, and results in stable GBM cell lines [53, 55] . Previous reports demonstrate that epigenetic mechanisms regulate the interconversion between slow-cycling and fast-cycling GBM cells [12, 56] . In comparison to fast-cycling GBM cells that relied on aerobic glycolysis for metabolism, transcriptional analysis showed that slow-cycling GBM cells displayed increased lipid content, up-regulation of autophagosome-lysosome genes, and preferentially used mitochondrial oxidative phosphorylation [13] . In contrast, we identified few differentially expressed genes in HDGC compared to LDGC fractions. Flow sorting of slow-cycling cells in label-retaining studies excluded cells with very low FSC levels, and did not include the HDGC fraction of GBM cells, suggesting that HDGCs may represent a novel population of label-retaining GBM cells characterized by a small cell volume.
Emergence of slow-cycling persister cells following receptor tyrosine kinase inhibition was dependent on expression of the histone lysine demethylase KDM6 in GBM tumorsphere cultures [6] . The slowcycling GBM cells were characterized by high Notch activity and increased stemness, including SOX9. Blockade of the mitochondrial respiratory chain reduced multidrug resistance in slow-cycling melanoma cells expressing high levels of JARD1B and KDM5 [57] . Interestingly, KDM5 is also overexpressed in slow-cycling GBM cells, and synergy was observed for combined treatment of TMZ and a histone deacetylase inhibitor [58] . It becomes increasingly clear that the slow-cycling state is governed by epigenetic mechanisms. Interestingly, T cell target antigens were overexpressed in slow-cycling GBM cells, providing a rationale for immunotherapy in preventing recurrence. Here, we have identified small GBM cells that have likely been ignored during previous neurohistological examinations and flow cytometry analysis of tumor biopsies. We have developed density gradient protocols that enable isolation of these HDGCs. Our results show that slow-cycling HDGCs are resistant to current standard of care, providing a rationale for regrowth and recurrence in patients.
